New oligo-β-(1,3)-glucan derivatives as immunostimulating agents

Oligo-β-(1,3)-glucans were chemically modified in order to introduce a structural variation specifically on the reducing end of the oligomers. The impact of well defined structural modulations was further studied on cancer cells and murin models to evaluate their cytotoxicity and immunostimulating potential.

New β-(1,3)-glucanyl-mannose conjugates were synthesized. The resulting small linear oligosaccharides indeed stimulate the immune defence in murine model even if they are not able to adopt helical arrangements.Figure optionsDownload as PowerPoint slide